|
1
|
Morris M, Eifel PJ, Lu J, Grigsby PW,
Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG:
Pelvic radiation with concurrent chemotherapy compared with pelvic
and para-aortic radiation for high risk cervical cancer. N Engl J
Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rose PG, Bundy BN, Watkins EB, Thigpen JT,
Deppe G, Maiman MA, Clarke-Pearson DL and Insalaco S: Concurrent
cisplatin-based radiotherapy and chemotherapy for locally advanced
cervical cancer. N Engl J Med. 340:1144–1153. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Whitney CW, Sause W, Bundy BN, Malfetano
JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL and Liao SY:
Randomized comparison of fluorouracil plus cisplatin versus
hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA
carcinoma of the cervix with negative para-aortic lymph nodes: a
Gynecologic Oncology Group and Southwest Oncology Group study. J
Clin Oncol. 17:1339–1348. 1999.
|
|
4
|
Pearcey R, Brundage M, Drouin P, Jeffrey
J, Johnston D, Lukka H, MacLean G, Souhami L, Stuart G and Tu D:
Phase III trial comparing radical radiotherapy with and without
cisplatin chemotherapy in patients with advanced squamous cell
cancer of the cervix. J Clin Oncol. 20:966–972. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eifel PJ, Winter K, Morris M, Levenback C,
Grigsby PW, Cooper J, Rotman M, Gershenson D and Mutch DG: Pelvic
irradiation with concurrent chemotherapy versus pelvic and
para-aortic irradiation for high-risk cervical cancer: an update of
Radiation Therapy Oncology Group trial (RTOG) 90–01. J Clin Oncol.
22:872–880. 2004.PubMed/NCBI
|
|
6
|
Green JA, Kirwan JM, Tierney JF, Symonds
P, Fresco L, Collingwood M and Williams CJ: Survival and recurrence
after concomitant chemotherapy and radiotherapy for cancer of the
uterine cervix: a systematic review and meta-analysis. Lancet.
358:781–786. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lukka H, Hirte H, Fyles A, Thomas G, Elit
L, Johnston M, Fung MF and Browman G: Concurrent cisplatin-based
chemotherapy plus radiotherapy for cervical cancer – a
meta-analysis. J Clin Oncol. 14:203–212. 2002.
|
|
8
|
Sugiyama T, Nishida T, Kumagai S, Nishino
S, Fujivoshi K, Okura N, Yakushiji M, Hiura M and Umesaki N:
Combination chemotherapy with irinotecan and cisplatin as
neoadjuvant in locally advanced cervical cancer. Br J Cancer.
81:95–98. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sugiyama T, Nishida T, Kataoka A, Imaishi
K, Komai K, Ushijima K, Hasuo Y, Ookura N and Yakushiji M:
Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a
new regimen for patients with advanced ovarian cancer. Acta Obstet
Gynecol Japan. 48:827–834. 1996.PubMed/NCBI
|
|
10
|
Takeuchi S, Dobashi K, Fujimoto S, et al:
A late phase II study of CPT-11 on uterine cervical cancer and
ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers.
Gan To Kagaku Ryoho. 18:1861–1689. 1991.PubMed/NCBI
|
|
11
|
Sugiyama T, Yakushiji M, Noda K, Ikeda M,
Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji
F, Takahashi T, Umesaki N, Sato S, Hatae M and Ohashi Y: Phase II
study of irinotecan and cisplatin as first-line chemotherapy in
advanced or recurrent cervical cancer. Oncology. 58:31–37. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bonomi P, Blessing JA, Stehman FB, DiSaia
PJ, Walton L and Major FJ: Randomized trial of three cisplatin dose
schedules in squamous-cell carcinoma of the cervix: a Gynecologic
Oncology Group study. J Clin Oncol. 3:1079–1085. 1985.PubMed/NCBI
|
|
13
|
Rose PG, Blessing JA, Gershenson DM and
McGehee R: Paclitaxel and cisplatin as first-line therapy in
recurrent or advanced squamous cell carcinoma of the cervix: a
Gynecologic Oncology Group study. J Clin Oncol. 17:2676–2680.
1999.
|
|
14
|
Moore DH, Blessing JA, McQuellon RP,
Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF
and Rocereto TF: Phase III study of cisplatin with or without
paclitaxel in stage IVB, recurrent, or persistent squamous cell
carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin
Oncol. 22:3113–3119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Takeuchi S, Noda K and Yakushiji M; CPT-11
Study Group on Gynecologic Malignancy. Late phase II study of
CPT-11, topoisomerase I inhibitor, in advance cervical carcinoma
(CC). Proc Am Soc Clin Oncol. 11:2241992.
|
|
16
|
Tierney J: Neoadjuvant chemotherapy for
locally advanced cervical cancer: a systematic review and
meta-analysis of individual patient data from 21 randomised trials.
Eur J Cancer. 39:2470–2486. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Benedetti-Panici P, Greggi S, Colombo A,
Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F,
Zola P, Mangioni C and Landoni F: Neoadjuvant chemotherapy and
radical surgery versus exclusive radiotherapy in locally advanced
squamous cell cervical cancer: results from the Italian Multicenter
Randomized study. J Clin Oncol. 20:179–188. 2002. View Article : Google Scholar
|
|
18
|
Napolitano C, Imperato F, Mossa B,
Framarino ML, Marziani R and Marzetti L: The role of neoadjuvant
chemotherapy for squamous cell cervical cancer (Ib-IIIb): a
long-term randomized trial. Eur J Gynaec Oncol. 14:51–59.
2002.PubMed/NCBI
|
|
19
|
Huang HJ, Chang TC, Hong JH, Tseng CJ,
Chou HH, Huang KG and Lai CH: Prognostic value of age and
histologic type in neoadjuvant chemotherapy plus radical surgery
for bulky (>4 cm) stage IB and IIA cervical carcinoma. Int J
Gynecol Cancer. 13:204–211. 2003. View Article : Google Scholar : PubMed/NCBI
|
